: Characterization of the immunoregulatory action of saikosaponin-d. Cellular immunology 1994, 159 (1) : 15–25.PubMedCrossRef 4. Ushio Y, Abe H: Inactivation of measles virus and herpes simplex virus by saikosaponin d. Planta medica 1992, 58 (2) : 171–3.PubMedCrossRef 5. Tundis R, Bonesi M, Deguin B, et al.: Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins
from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae). Bioorganic buy Nivolumab & medicinal chemistry 2009, 17 (13) : 4542–7.CrossRef 6. Hsu YL, Kuo PL, Lin CC: The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells. Life sciences 2004, 75 (10) : 1231–42.PubMedCrossRef 7. Hsu YL, see more Kuo PL, Chiang LC, Lin CC: Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer letters 2004, 213 (2) : 213–21.PubMedCrossRef 8. Chen JC, Chang NW, Chung JG, Chen KC: Saikosaponin-A induces apoptotic
mechanism in human breast MDA-MB-231 and MCF-7 cancer cells. The American journal of Chinese medicine 2003, 31 (3) : 363–77.PubMedCrossRef 9. Motoo Y, Sawabu N: Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer letters 1994, 86 (1) : 91–5.PubMedCrossRef 10. Cohen SM, Lippard SJ: Cisplatin: from DNA damage to cancer chemotherapy. Progress in nucleic acid research and molecular biology 2001, 67: 93–130.PubMedCrossRef 11. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998, 34 (10) : 1535–42.PubMedCrossRef 12. Niedner H, Christen R, Lin X, Kondo A, Howell SB: Identification of genes that mediate sensitivity to cisplatin. Molecular pharmacology 2001, 60 (6) : 1153–60.PubMed 13. Mansouri A, Ridgway LD, Korapati AL, et al.: Sustained activation L-gulonolactone oxidase of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. The Journal of biological chemistry 2003, 278 (21) : 19245–56.PubMedCrossRef 14. Bandyopadhyay K, Baneres JL, Martin A,
Blonski C, Parello J, Gjerset RA: Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization. Cell cycle (Georgetown, Tex) 2009, 8 (17) : 2779–88.CrossRef 15. Lopez G, Liu J, Ren W, et al.: Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009, 15 (10) : 3472–83.PubMedCrossRef 16. Sun Q, Sakaida T, Yue W, Gollin SM, Yu J: Chemosensitization of head and neck cancer cells by PUMA. Molecular cancer therapeutics 2007, 6 (12 Pt 1) : 3180–8.PubMedCrossRef 17. Biliran H, Banerjee S, Thakur A, et al.: c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin Cancer Res 2007, 13 (9) : 2811–21.